{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:38:30Z","timestamp":1786649910422,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:p>\n                    Bevacizumab is a drug that is widely used for the first-line treatment of metastatic colorectal cancer (mCRC). Bevacizumab neutralizes vascular endothelial growth factor and can lead to proteinuria and renal damage. In this case, experience on full dose short-time treatment of bevacizumab in a patient under immunosuppressive treatment for renal transplantation with chronic renal failure has been shared. The patients were diagnosed with mCRC 7 months ago. The patient had multiple liver metastases at the time of the diagnosis. He had a history of renal transplantation 2 years ago because of renal failure, and he had been under immunosuppressive treatment for this reason. 5-fluorouracil-leucovorin-irinotecan -bevacizumab regimen was begun for the treatment of mCRC. The dose of bevacizumab was 5 mg\/kg\/day for 14 days. There was 2.5 g\/day of proteinuria at the start of the treatment. However, renal dysfunction progressed, and proteinuria increased to 4 g\/day in the 3\n                    <jats:sup>rd<\/jats:sup>\n                    month of treatment. In this case, the experience of using bevacizumab in a patient under immunosuppressive treatment for renal transplantation with chronic failure has been presented.\n                  <\/jats:p>","DOI":"10.4103\/0973-1482.168996","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T01:07:21Z","timestamp":1455844041000},"page":"1018-1020","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Experience of bevacizumab in a patient with colorectal cancer after renal transplantation"],"prefix":"10.4103","volume":"11","author":[{"given":"Fatma Yal\u00e7\u0131n","family":"M\u00fcsri","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Mutlu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melek Karakurt","family":"Ery\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya K\u0131vrak","family":"Salim","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan \u015eenol","family":"Co\u015fkun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,2,15]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1111\/j.1600-6143.2010.03231.x","article-title":"Increased incidence of colorectal malignancies in renal transplant recipients: A case control study","volume":"10","author":"Park","year":"2010","journal-title":"Am J Transplant"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.critrevonc.2005.03.012","article-title":"Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy","volume":"56","author":"Taylor","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","article-title":"Colorectal cancer","volume":"383","author":"Brenner","year":"2014","journal-title":"Lancet"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","article-title":"PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer","volume":"32","author":"Schwartzberg","year":"2014","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"R5-20260109","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1634\/theoncologist.9-suppl_1-2","article-title":"Vascular endothelial growth factor as a target for anticancer therapy","volume":"9","author":"Ferrara","year":"2004","journal-title":"Oncologist"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J Clin Oncol"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.2010020167","article-title":"Bevacizumab increases risk for severe proteinuria in cancer patients","volume":"21","author":"Wu","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(07)70037-2","article-title":"Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma","volume":"8","author":"Frangi\u00e9","year":"2007","journal-title":"Lancet Oncol"},{"key":"R11-20260109","first-page":"36","article-title":"Progressive bevacizumab-associated renal thrombotic microangiopathy","volume":"2","author":"Uy","year":"2009","journal-title":"NDT Plus"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00467-014-3036-8","article-title":"De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus","volume":"30","author":"Cortina","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1016\/j.ajkd.2003.07.011","article-title":"Use of tacrolimus in steroid- and cyclophosphamide-resistant minimal change nephrotic syndrome","volume":"42","author":"Tang","year":"2003","journal-title":"Am J Kidney Dis"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201511040-00075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:47Z","timestamp":1786647587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201511040-00075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.168996","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}